TY - JOUR T1 - A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin®) as a resuscitative agent in hypovolemic shock patients JF - medRxiv DO - 10.1101/2020.07.30.20068114 SP - 2020.07.30.20068114 AU - Anil Gulati AU - Rajat Choudhuri AU - Ajay Gupta AU - Saurabh Singh AU - S. K. Noushad Ali AU - Gursaran Kaur Sidhu AU - Parvez David Haque AU - Prashant Rahate AU - Aditya R Bothra AU - G P Singh AU - Sanjeev Maheshwari AU - Deepak Jeswani AU - Sameer Haveri AU - Apurva Agarwal AU - Nilesh Radheshyam Agrawal Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/05/2020.07.30.20068114.abstract N2 - Centhaquine is a novel, first-in-class resuscitative agent for the treatment of hypovolemic shock. Efficacy of centhaquine for the treatment of hypovolemic shock as an adjuvant to standard of care (SOC) was evaluated in a prospective, multi-center, randomized, double-blind, controlled phase III study. Key inclusion criteria were, systolic blood pressure (SBP) of ≤90 mm Hg, blood lactate levels of ≥2 mmol/L and patients receiving SOC in a hospital or ICU setting. Primary endpoints of the study were change in SBP, diastolic blood pressure (DBP), blood lactate levels and base deficit. Mortality through day 28 was the key secondary endpoint. A total of 197 patients were screened, of which 105 patients met eligibility criteria and were included in the study. Patients were randomized in a 2:1 ratio, 71 patients to centhaquine (0.01 mg/kg, IV infusion) group and 34 patients to control group. SOC was provided to both centhaquine and control groups. Demographics were similar in both groups, except patients in saline group were few years younger. Difference between the mean in control and centhaquine groups of hemoglobin level was 0.769 ± 0.590 (P=0.0984) and in hematocrit level was 2.419 ± 1.899 (P=0.1036) at the time of inclusion. Centhaquine substantially reduced 28-day all-cause mortality. In control group, mortality rate was 11.76% compared to 2.94% in centhaquine group (odds ratio: 4.4; 95% CI 0.9651 to 23.74 and P=0.037). At 24 hours of resuscitation, SBP of more than 110 mmHg was in 60.61% patients of control and 79.69% patients of centhaquine group (P=0.0222; OR=2.55); while DBP of more than 70 mmHg was in 51.52% patients of control and 76.56% patients of centhaquine group (P=0.0061; OR=3.075). The number of patients with blood lactate levels of 1.5 mmol/L or less were 46.88% in control group compared to 69.35% in centhaquine group (P=0.0168; OR=2.565). The number of patients with base-deficit of less than minus 2 were 43.75% in control group compared to 69.84% in centhaquine group (P=0.0069; OR=2.977). Shock index improved in centhaquine but not in control group in the first 6 hours of resuscitation. Centhaquine improved acute respiratory distress syndrome (ARDS) and multiple organ dysfunction score (MODS). No drug related adverse event was reported. Centhaquine (Lyfaquin®) is a highly efficacious resuscitative agent for the treatment of hypovolemic shock as an adjuvant to SOC.Competing Interest StatementAnil Gulati is a stockholder and employee of Pharmazz, Inc. All other authors have no competing interest to declare.Clinical TrialNCT04045327 (Clinical Trials Registry, India CTRI/2019/01/017196). The study protocol (PMZ-2010/CT-3.1/2018) was approved by the Drug Controller General of India (DCGI), Ministry of Health and Family Welfare, Government of India and Institutional Ethics Committee of all the 14 Institutions.Funding StatementThe present study was funded by Pharmazz, Inc. Toxicological study of centhaquine in dog was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R43HL137469.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not publicly available due to restrictions that could compromise the privacy of research participants. The data that support the findings of this study are available from the corresponding author, upon reasonable request. The study protocol (PMZ-2010/CT-3.1/2018) was approved by the Drug Controller General of India (DCGI), Ministry of Health and Family Welfare, Government of India and Institutional Ethics Committee of all the 14 Institutions. ER -